Vistin Pharma ASA

Vistin Pharma is Europe’s only dedicated producer of Metformin hydrochloride, the active ingredient in the world’s most prescribed diabetes drug. Based in Kragerø, Norway, the company holds about 10% of the global metformin API market — a position earned through decades of chemical manufacturing expertise, secured renewable energy contracts until 2032, and a strong regulatory moat that discourages competitors.

The stock trades on the Oslo Stock Exchange with the ticker VISTN at NOK 21.60, giving the company a market cap of roughly NOK 960 million. It recently posted its best year ever — record volume of 5800 metric tonnes, highest EBITDA of NOK 115 million, and a 19% increase in earnings per share.

As a small-cap company operating at full capacity, it returns substantial cash to shareholders, has no debt, and trades as if these factors are insignificant. The quantitative case appears more cautious — a neutral risk/return profile with expected returns barely exceeding the risk-free rate, supported by the Omega Ratio indicating that, although modest, the asymmetry favours investors.

Ultimately, Vistin Pharma tests investors' conviction: whether they believe that top-quality at a significant discount will eventually be recognised, or whether the market’s lack of interest is just the cost of being a NOK 960 million company producing a single molecule in one plant in southern Norway.